Blocking or removing immune-suppressing cells allows a special type of chemotherapy — and the immune cells it activates — to destroy prostate tumors, researchers report. This novel combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer.